Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Surrozen (Nasdaq: SRZN) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) dated April 24, 2026. The company granted a non-statutory stock option for 2,020 shares to a newly hired non-executive employee under the 2025 Equity Inducement Plan.
The option exercise price is $28.14 per share (Nasdaq closing price on April 24, 2026). The option vests over four years: 25% at the one-year anniversary and the remainder ratably each month over 36 months, subject to continued service.
Positive
- None.
Negative
- None.
News Market Reaction – SRZN
In the Apr 29 session, SRZN gained 1.87%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.0% during that session. Argus tracked a trough of -7.3% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Earnings and update | Negative | -0.9% | Reported FY2025 net loss and cash position with pipeline and IND plans. |
| Feb 25 | Conference presentation | Neutral | -4.7% | Announcement of TD Cowen healthcare conference fireside chat and webcast. |
| Feb 23 | Inducement option grant | Neutral | +1.6% | Non-statutory option for 3,070 shares to a new non-executive employee. |
| Feb 05 | Conference presentation | Neutral | +7.3% | Guggenheim biotech summit presentation with live and archived webcast. |
| Nov 25 | Conference presentations | Neutral | +2.7% | Scheduled fireside discussions at two December 2025 healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including conferences, inducement grants and earnings, has typically led to modest single-digit moves, mostly aligned with the neutral-to-slightly-negative tone of updates.
Over the last several months, Surrozen’s news flow has focused on investor outreach, financing milestones and pipeline progress. On Mar 23, 2026, earnings highlighted a $5.0M milestone from Boehringer Ingelheim and cash of $89.2M, alongside a full-year net loss of $242.0M. Multiple conference appearances in early 2026 and late 2025 signaled active investor engagement. A prior inducement grant on Feb 23, 2026 also carried similar four-year vesting terms, making today’s option award consistent with recent HR-related updates.
Key Terms
non-statutory stock option financial
nasdaq listing rule 5635(c)(4) regulatory
equity inducement plan financial
wnt signaling medical
ophthalmic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on April 24, 2026, Surrozen granted a non-statutory stock option for an aggregate of 2,020 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.
The stock option was granted under Surrozen’s 2025 Equity Inducement Plan which provides for the grant of equity awards to new employees of Surrozen in accordance with Nasdaq Listing Rule 5635(c)(4). The grant was approved by the Compensation Committee of the Surrozen Board of Directors and provides for the purchase of shares of Surrozen common stock at a price of
The stock option vests over a four-year period, with 25 percent of the shares underlying the option vesting on the one-year anniversary of the employee’s date of hire, and the remaining shares vesting ratably each month thereafter over 36 months, subject to the employee’s continuous service as of each such vesting date.
About Surrozen
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates); Surrozen’s intention to submit an IND application for SZN-8141 in 2026; and expectations regarding Surrozen’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact:
Email: Investorinfo@surrozen.com
